PRESS RELEASE: Viragen International’s Subsidiary, ViraNative AB, Files to Seek Bankruptcy Protection in Sweden

Viragen International’s Subsidiary, ViraNative AB, Files to Seek Bankruptcy Protection in Sweden

PLANTATION, FLORIDA – September 14, 2007 – Viragen and  its majority-owned subsidiary, Viragen International, today jointly announced that Viragen International’s wholly-owned subsidiary, ViraNative AB, located in Umeå, Sweden, filed an application seeking protection under the bankruptcy laws of Sweden.  ViraNative manufactures Multiferon®, a multi-subtype, human alpha interferon.

The bankruptcy application was filed in the District Court of Umeå, under Case Number K1767-07.  The application was filed because ViraNative was unable to pay taxes and other debts.

The bankruptcy court has appointed Anders Bergman of Ackordscentralen Norrland AB as bankruptcy administrator for ViraNative.  It is the responsibility of the administrator to inventory the assets of the bankrupt and to identify the creditors and the amount of their claims.  The bankruptcy administrator will also seek to identify purchasers for the assets of ViraNative and process their orderly liquidation and sale in accordance with Swedish laws.  Mr. Bergman can be reached by telephone at: +46 (0) 90-70 62 00; and by email at: [email protected].

While Viragen, Inc. continues to seek new sources of working capital to fund its operations, and the operations of Viragen International, Inc., the Companies do not intend to fund further operations of ViraNative during the bankruptcy process.  Therefore, ViraNative’s operations may be disrupted or halted.  Viragen, Inc. and Viragen International, Inc. are monitoring the bankruptcy proceedings but at this stage cannot predict what impact the proceedings may have on their respective operations.

About Viragen International, Inc.:

Viragen International, Inc. (OTC BB: “VRGE”) is a majority-owned subsidiary of Viragen, Inc. (OTC BB: “VRAI”), and operates through its wholly-owned subsidiary, Viragen (Scotland) Limited, located near Edinburgh, Scotland.  Viragen Scotland is engaged in the research and development of novel therapeutic proteins that disrupt the advance of life-threatening diseases, with a focus on cancers.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.